Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Combined interventions to reduce HIV incidence in KwaZulu-Natal: a modelling study

Authors: Stéphanie Blaizot, Helena Huerga, Benjamin Riche, Tom Ellman, Amir Shroufi, Jean-François Etard, René Ecochard

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Combined prevention interventions, including early antiretroviral therapy initiation, may substantially reduce HIV incidence in hyperendemic settings. Our aim was to assess the potential short-term impact of combined interventions on HIV spreading in the adult population of Mbongolwane and Eshowe (KwaZulu-Natal, South Africa) using sex- and age-specific scenarios, and age-targeted interventions.

Methods

A mathematical model was used with data on adults (15–59 years) from the Mbongolwane and Eshowe HIV Impact in Population Survey to compare the effects of various interventions on the HIV incidence rate. These interventions included increase in antiretroviral therapy (ART) coverage with extended eligibility criteria, increase in voluntary medical male circumcision (VMMC), and implementation of pre-exposure prophylaxis (PrEP) among women.

Results

With no additional interventions to the ones in place at the time of the survey (ART at CD4 < 350 and VMMC), incidence will decrease by 24% compared to the baseline rate. The implementation of “ART at CD4<500” or “ART for all” would reduce further the incidence rate by additional 8% and 15% respectively by 4 years and 20% and 34% by 10 years. Impacts would be higher with age-targeted scenarios than without.

Conclusions

In Mbongolwane and Eshowe, implementation of the new South African guidelines, recommending ART initiation regardless of CD4 count, would accelerate incidence reduction. In this setting, combining these guidelines, VMMC, and PrEP among young women could be an effective strategy in reducing the incidence to low levels.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shisana O, Rehle T, Simbayi L, Zuma K, Jooste S, Zungu N, Labadarios D, Onoya D. South African National HIV Prevalence, Incidence and Behaviour Survey, 2012. Cape Town: HSRC Press; 2014. Shisana O, Rehle T, Simbayi L, Zuma K, Jooste S, Zungu N, Labadarios D, Onoya D. South African National HIV Prevalence, Incidence and Behaviour Survey, 2012. Cape Town: HSRC Press; 2014.
2.
go back to reference Joint United Nations Programme on HIV/AIDS (UNAIDS). 90–90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2014. Joint United Nations Programme on HIV/AIDS (UNAIDS). 90–90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2014.
3.
go back to reference Castelnuovo B, Musaazi J, Musomba R, Ratanshi RP, Kiragga AN. Quantifying retention during pre-antiretroviral treatment in a large urban clinic in Uganda. BMC Infect Dis. 2015;15:252.CrossRefPubMedPubMedCentral Castelnuovo B, Musaazi J, Musomba R, Ratanshi RP, Kiragga AN. Quantifying retention during pre-antiretroviral treatment in a large urban clinic in Uganda. BMC Infect Dis. 2015;15:252.CrossRefPubMedPubMedCentral
4.
go back to reference Jean K, Puren A, Cutler E, Singh B, Bouscaillou J, Rain-Taljaard R, Taljaard D, Gouws E, Lissouba P, Lewis DA, et al. Level of viral suppression and the cascade of HIV care in a South African semi-urban setting in 2012. AIDS. 2016;30(13):2107–16.CrossRefPubMed Jean K, Puren A, Cutler E, Singh B, Bouscaillou J, Rain-Taljaard R, Taljaard D, Gouws E, Lissouba P, Lewis DA, et al. Level of viral suppression and the cascade of HIV care in a South African semi-urban setting in 2012. AIDS. 2016;30(13):2107–16.CrossRefPubMed
5.
go back to reference MacLeod WB, Fraser N, Bor J, Shubber Z, Carmona S, Pillay Y, Gorgens M: Analysis of age- and sex-specific HIV care cascades in South Africa suggests unequal progress towards UNAIDS 90–90-90 treatment targets. 21st International AIDS Conference: 18–22 July 2016; Durban, South Africa. MacLeod WB, Fraser N, Bor J, Shubber Z, Carmona S, Pillay Y, Gorgens M: Analysis of age- and sex-specific HIV care cascades in South Africa suggests unequal progress towards UNAIDS 90–90-90 treatment targets. 21st International AIDS Conference: 18–22 July 2016; Durban, South Africa.
6.
go back to reference Takuva S, Brown A, Macleod W, Pillay Y, Delpech V, Puren A: Disparities in engagement within HIV care in South Africa. Conference on Retroviruses and Opportunistic Infections: 2015; Seattle, USA. Takuva S, Brown A, Macleod W, Pillay Y, Delpech V, Puren A: Disparities in engagement within HIV care in South Africa. Conference on Retroviruses and Opportunistic Infections: 2015; Seattle, USA.
7.
go back to reference WHO Regional Office for Africa. Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa: 2012. Brazzaville: WHO Regional Office for Africa; 2013. WHO Regional Office for Africa. Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa: 2012. Brazzaville: WHO Regional Office for Africa; 2013.
8.
go back to reference Joint United Nations Programme on HIV/AIDS (UNAIDS). The gap report. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2014. Joint United Nations Programme on HIV/AIDS (UNAIDS). The gap report. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2014.
9.
go back to reference Harrison A, Colvin CJ, Kuo C, Swartz A, Lurie M. Sustained high HIV incidence in young women in Southern Africa: social, behavioral, and structural factors and emerging intervention approaches. Curr Hiv-Aids Rep. 2015;12(2):207–15.CrossRef Harrison A, Colvin CJ, Kuo C, Swartz A, Lurie M. Sustained high HIV incidence in young women in Southern Africa: social, behavioral, and structural factors and emerging intervention approaches. Curr Hiv-Aids Rep. 2015;12(2):207–15.CrossRef
10.
go back to reference Statistics South Africa. Census 2011 Statistical release - P0301.4. Pretoria: Statistics South Africa; 2012. Statistics South Africa. Census 2011 Statistical release - P0301.4. Pretoria: Statistics South Africa; 2012.
11.
go back to reference Huerga H, Van Cutsem G, Ben Farhat J, Reid M, Bouhenia M, Maman D, Wiesner L, Etard JF, Ellman T. Who needs to be targeted for HIV testing and treatment in KwaZulu-Natal? Results from a population-based survey. J Acquir Immune Defic Syndr. 2016;73(4):411–8.CrossRefPubMedPubMedCentral Huerga H, Van Cutsem G, Ben Farhat J, Reid M, Bouhenia M, Maman D, Wiesner L, Etard JF, Ellman T. Who needs to be targeted for HIV testing and treatment in KwaZulu-Natal? Results from a population-based survey. J Acquir Immune Defic Syndr. 2016;73(4):411–8.CrossRefPubMedPubMedCentral
12.
go back to reference Blaizot S, Riche B, Maman D, Mukui I, Kirubi B, Etard JF, Ecochard R. Estimation and short-term prediction of the course of the hiv epidemic using demographic and health survey methodology-like data. PLoS One. 2015;10(6):e0130387.CrossRefPubMedPubMedCentral Blaizot S, Riche B, Maman D, Mukui I, Kirubi B, Etard JF, Ecochard R. Estimation and short-term prediction of the course of the hiv epidemic using demographic and health survey methodology-like data. PLoS One. 2015;10(6):e0130387.CrossRefPubMedPubMedCentral
13.
go back to reference Blaizot S, Maman D, Riche B, Mukui I, Kirubi B, Ecochard R, Etard JF. Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study. BMC Infect Dis. 2016;16:189.CrossRefPubMedPubMedCentral Blaizot S, Maman D, Riche B, Mukui I, Kirubi B, Ecochard R, Etard JF. Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study. BMC Infect Dis. 2016;16:189.CrossRefPubMedPubMedCentral
14.
go back to reference Nyirenda M, Hosegood V, Barnighausen T, Newell ML. Mortality levels and trends by HIV serostatus in rural South Africa. AIDS. 2007;21(Suppl 6):S73–9.CrossRefPubMed Nyirenda M, Hosegood V, Barnighausen T, Newell ML. Mortality levels and trends by HIV serostatus in rural South Africa. AIDS. 2007;21(Suppl 6):S73–9.CrossRefPubMed
15.
go back to reference Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298.CrossRefPubMedPubMedCentral Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298.CrossRefPubMedPubMedCentral
16.
go back to reference Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643–56.CrossRefPubMed Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643–56.CrossRefPubMed
17.
go back to reference Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657–66.CrossRefPubMed Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657–66.CrossRefPubMed
18.
go back to reference World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015.
19.
go back to reference Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRefPubMedPubMedCentral Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRefPubMedPubMedCentral
20.
go back to reference Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.CrossRefPubMed Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.CrossRefPubMed
21.
go back to reference Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JAC, Humair S, Kerr CC, Klein DJ, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2014;2(1):E23–34.CrossRefPubMed Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JAC, Humair S, Kerr CC, Klein DJ, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2014;2(1):E23–34.CrossRefPubMed
22.
go back to reference Abuelezam NN, McCormick AW, Fussell T, Afriyie AN, Wood R, DeGruttola V, Freedberg KA, Lipsitch M, Seage GR. Can the heterosexual HIV epidemic be eliminated in South Africa using combination prevention? A modeling analysis. Am J Epidemiol. 2016;184(3):239–48.CrossRefPubMed Abuelezam NN, McCormick AW, Fussell T, Afriyie AN, Wood R, DeGruttola V, Freedberg KA, Lipsitch M, Seage GR. Can the heterosexual HIV epidemic be eliminated in South Africa using combination prevention? A modeling analysis. Am J Epidemiol. 2016;184(3):239–48.CrossRefPubMed
23.
go back to reference Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings. AIDS. 2010;24(5):729–U128.CrossRefPubMedPubMedCentral Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings. AIDS. 2010;24(5):729–U128.CrossRefPubMedPubMedCentral
24.
go back to reference Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JAC, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9(7):e1001245.CrossRefPubMedPubMedCentral Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JAC, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9(7):e1001245.CrossRefPubMedPubMedCentral
25.
go back to reference Hontelez JAC, Lurie MN, Barnighausen T, Bakker R, Baltussen R, Tanser F, Hallett TB, Newell ML, de Vlas SJ. Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med. 2013;10(10):e1001534.CrossRefPubMedPubMedCentral Hontelez JAC, Lurie MN, Barnighausen T, Bakker R, Baltussen R, Tanser F, Hallett TB, Newell ML, de Vlas SJ. Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med. 2013;10(10):e1001534.CrossRefPubMedPubMedCentral
26.
go back to reference Johnson LF, Dorrington RE. Modelling the demographic impact of HIV/AIDS in South Africa and the likely impact of interventions. Demogr Res. 2006;14:541–73.CrossRef Johnson LF, Dorrington RE. Modelling the demographic impact of HIV/AIDS in South Africa and the likely impact of interventions. Demogr Res. 2006;14:541–73.CrossRef
27.
go back to reference Johnson LF, White PJ. A review of mathematical models of HIV/AIDS interventions and their implications for policy. Sex Transm Infect. 2011;87(7):629–34.CrossRefPubMed Johnson LF, White PJ. A review of mathematical models of HIV/AIDS interventions and their implications for policy. Sex Transm Infect. 2011;87(7):629–34.CrossRefPubMed
28.
go back to reference Long EF, Stavert RR. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. J Gen Intern Med. 2013;28(10):1294–301.CrossRefPubMedPubMedCentral Long EF, Stavert RR. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. J Gen Intern Med. 2013;28(10):1294–301.CrossRefPubMedPubMedCentral
29.
go back to reference Joint United Nations Programme on HIV/AIDS (UNAIDS). Combination HIV prevention: tailoring and coordinating biomedical, behavioural and structural strategies to reduce new HIV infections. A UNAIDS Discussion Paper. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2010. Joint United Nations Programme on HIV/AIDS (UNAIDS). Combination HIV prevention: tailoring and coordinating biomedical, behavioural and structural strategies to reduce new HIV infections. A UNAIDS Discussion Paper. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2010.
30.
go back to reference Brown G, Reeders D, Dowsett GW, Ellard J, Carman M, Hendry N, Wallace J. Investigating combination HIV prevention: isolated interventions or complex system. J Int AIDS Soc. 2015;18:20499.CrossRefPubMedPubMedCentral Brown G, Reeders D, Dowsett GW, Ellard J, Carman M, Hendry N, Wallace J. Investigating combination HIV prevention: isolated interventions or complex system. J Int AIDS Soc. 2015;18:20499.CrossRefPubMedPubMedCentral
31.
go back to reference Shanaube K, Bock P. Innovative strategies for scale up of effective combination HIV prevention interventions in Sub-Saharan Africa. Curr Hiv-Aids Rep. 2015;12(2):231–7.CrossRef Shanaube K, Bock P. Innovative strategies for scale up of effective combination HIV prevention interventions in Sub-Saharan Africa. Curr Hiv-Aids Rep. 2015;12(2):231–7.CrossRef
32.
go back to reference Anderson SJ, Cherutich P, Kilonzo N, Cremin I, Fecht D, Kimanga D, Harper M, Masha RL, Ngongo PB, Maina W, et al. Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study. Lancet. 2014;384(9939):249–56.CrossRefPubMed Anderson SJ, Cherutich P, Kilonzo N, Cremin I, Fecht D, Kimanga D, Harper M, Masha RL, Ngongo PB, Maina W, et al. Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study. Lancet. 2014;384(9939):249–56.CrossRefPubMed
33.
go back to reference Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27(3):447–58.CrossRefPubMed Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27(3):447–58.CrossRefPubMed
34.
go back to reference Johnson LF, Chiu C, Myer L, Davies MA, Dorrington RE, Bekker LG, Boulle A, Meyer-Rath G. Prospects for HIV control in South Africa: a model-based analysis. Glob Health Action. 2016;9 Johnson LF, Chiu C, Myer L, Davies MA, Dorrington RE, Bekker LG, Boulle A, Meyer-Rath G. Prospects for HIV control in South Africa: a model-based analysis. Glob Health Action. 2016;9
35.
go back to reference McGillen JB, Anderson SJ, Dybul MR, Hallett TB. Optimum resource allocation to reduce HIV incidence across sub-Saharan Africa: a mathematical modelling study. Lancet Hiv. 2016;3(9):E441–8.CrossRefPubMed McGillen JB, Anderson SJ, Dybul MR, Hallett TB. Optimum resource allocation to reduce HIV incidence across sub-Saharan Africa: a mathematical modelling study. Lancet Hiv. 2016;3(9):E441–8.CrossRefPubMed
36.
go back to reference Smith JA, Anderson SJ, Harris KL, McGillen JB, Lee E, Garnett GP, Hallett TB. Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study. Lancet HIV. 2016;3(7):e289–96.CrossRefPubMedPubMedCentral Smith JA, Anderson SJ, Harris KL, McGillen JB, Lee E, Garnett GP, Hallett TB. Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study. Lancet HIV. 2016;3(7):e289–96.CrossRefPubMedPubMedCentral
37.
go back to reference Alsallaq RA, Baeten JM, Celum CL, Hughes JP, Abu-Raddad LJ, Barnabas RV, Hallett TB. Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community. PLoS One. 2013;8(1):e54575.CrossRefPubMedPubMedCentral Alsallaq RA, Baeten JM, Celum CL, Hughes JP, Abu-Raddad LJ, Barnabas RV, Hallett TB. Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community. PLoS One. 2013;8(1):e54575.CrossRefPubMedPubMedCentral
38.
go back to reference Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, Eaton JW, Hauck K, Smith P, Griffith S, et al. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One. 2014;9(1):e84511.CrossRefPubMedPubMedCentral Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, Eaton JW, Hauck K, Smith P, Griffith S, et al. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One. 2014;9(1):e84511.CrossRefPubMedPubMedCentral
39.
go back to reference Iwuji C, Orne-Gliemann J, Balestre E, Larmarange J, Thiebaut R, Tanser F, Okesola N, Makowa T, Dreyer J, Herbst K et al: The impact of universal test and treat on HIV incidence in a rural South African population. 21st International AIDS conference: 18–22 July 2016; Durban, South Africa. Iwuji C, Orne-Gliemann J, Balestre E, Larmarange J, Thiebaut R, Tanser F, Okesola N, Makowa T, Dreyer J, Herbst K et al: The impact of universal test and treat on HIV incidence in a rural South African population. 21st International AIDS conference: 18–22 July 2016; Durban, South Africa.
41.
go back to reference Steele SJ, Arellano F, Ellman T, Shroufi A, Van Cutsem G. Extended ART initiation criteria can be implemented successfully in rural South Africa. 21st International AIDS Conference: 18–22 July 2016; Durban, South Africa. Steele SJ, Arellano F, Ellman T, Shroufi A, Van Cutsem G. Extended ART initiation criteria can be implemented successfully in rural South Africa. 21st International AIDS Conference: 18–22 July 2016; Durban, South Africa.
42.
go back to reference Wood E, Kerr T, Marshall BDL, Li K, Zhang R, Hogg RS, Harrigan PR, Montaner JSG. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. Brit Med J. 2009;338:b1649. Wood E, Kerr T, Marshall BDL, Li K, Zhang R, Hogg RS, Harrigan PR, Montaner JSG. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. Brit Med J. 2009;338:b1649.
43.
go back to reference Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, Colfax GN. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068.CrossRefPubMedPubMedCentral Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, Colfax GN. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068.CrossRefPubMedPubMedCentral
44.
go back to reference Castel AD, Befus M, Willis S, Griffin A, West T, Hader S, Greenberg AE. Use of the community viral load as a population-based biomarker of HIV burden. AIDS. 2012;26(3):345–53.CrossRefPubMed Castel AD, Befus M, Willis S, Griffin A, West T, Hader S, Greenberg AE. Use of the community viral load as a population-based biomarker of HIV burden. AIDS. 2012;26(3):345–53.CrossRefPubMed
45.
go back to reference Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S122–9.CrossRefPubMedPubMedCentral Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S122–9.CrossRefPubMedPubMedCentral
46.
go back to reference Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Matovu Kiweewa F, Nair G, Mhlanga F, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121-32. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Matovu Kiweewa F, Nair G, Mhlanga F, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121-32.
47.
go back to reference Jackson A, McGowan I. Long-acting rilpivirine for HIV prevention. Curr Opin HIV AIDS. 2015;10(4):253–7.CrossRefPubMed Jackson A, McGowan I. Long-acting rilpivirine for HIV prevention. Curr Opin HIV AIDS. 2015;10(4):253–7.CrossRefPubMed
48.
go back to reference Hontelez JA, Chang AY, Ogbuoji O, de Vlas SJ, Barnighausen T, Atun R. Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa: investment needs, population health gains, and cost-effectiveness. AIDS. 2016;30(15):2341–50.CrossRefPubMedPubMedCentral Hontelez JA, Chang AY, Ogbuoji O, de Vlas SJ, Barnighausen T, Atun R. Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa: investment needs, population health gains, and cost-effectiveness. AIDS. 2016;30(15):2341–50.CrossRefPubMedPubMedCentral
49.
go back to reference Glaubius RL, Hood G, Penrose KJ, Parikh UM, Mellors JW, Bendavid E, Abbas UL. Cost-effectiveness of injectable preexposure prophylaxis for HIV prevention in South Africa. Clin Infect Dis. 2016;63(4):539–47.CrossRefPubMed Glaubius RL, Hood G, Penrose KJ, Parikh UM, Mellors JW, Bendavid E, Abbas UL. Cost-effectiveness of injectable preexposure prophylaxis for HIV prevention in South Africa. Clin Infect Dis. 2016;63(4):539–47.CrossRefPubMed
50.
go back to reference Walensky RP, Jacobsen MM, Bekker LG, Parker RA, Wood R, Resch SC, Horstman NK, Freedberg KA, Paltiel AD. Potential clinical and economic value of long-acting preexposure prophylaxis for South African women at high-risk for HIV infection. J Infect Dis. 2016;213(10):1523–31.CrossRefPubMed Walensky RP, Jacobsen MM, Bekker LG, Parker RA, Wood R, Resch SC, Horstman NK, Freedberg KA, Paltiel AD. Potential clinical and economic value of long-acting preexposure prophylaxis for South African women at high-risk for HIV infection. J Infect Dis. 2016;213(10):1523–31.CrossRefPubMed
51.
go back to reference Alistar SS, Grant PM, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med. 2014;12:46.CrossRefPubMedPubMedCentral Alistar SS, Grant PM, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med. 2014;12:46.CrossRefPubMedPubMedCentral
52.
go back to reference Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10(3):e1001401.CrossRefPubMedPubMedCentral Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10(3):e1001401.CrossRefPubMedPubMedCentral
53.
go back to reference Abdool Karim Q: Assessing data supporting HIV prevention approaches. 21st International AIDS Conference: 18–22 July 2016; Durban, South Africa. Abdool Karim Q: Assessing data supporting HIV prevention approaches. 21st International AIDS Conference: 18–22 July 2016; Durban, South Africa.
54.
go back to reference Dellar RC, Dlamini S, Karim QA. Adolescent girls and young women: key populations for HIV epidemic control. J Int AIDS Soc. 2015;18:64–70.CrossRef Dellar RC, Dlamini S, Karim QA. Adolescent girls and young women: key populations for HIV epidemic control. J Int AIDS Soc. 2015;18:64–70.CrossRef
55.
go back to reference Akullian A, Bershteyn A, Klein D, Vandormael A, Barnighausen T, Tanser F. Sexual partnership age pairings and risk of HIV acquisition in rural South Africa. AIDS. 2017;31(12):1755-64. Akullian A, Bershteyn A, Klein D, Vandormael A, Barnighausen T, Tanser F. Sexual partnership age pairings and risk of HIV acquisition in rural South Africa. AIDS. 2017;31(12):1755-64.
56.
go back to reference Gouws E, Cuchi P, I ICEH. Focusing the HIV response through estimating the major modes of HIV transmission: a multi-country analysis. Sex Transm Infect. 2012;88:I76–85.CrossRefPubMedPubMedCentral Gouws E, Cuchi P, I ICEH. Focusing the HIV response through estimating the major modes of HIV transmission: a multi-country analysis. Sex Transm Infect. 2012;88:I76–85.CrossRefPubMedPubMedCentral
57.
go back to reference Mulongeni P, Johnson L. Epidemiological synergy: the role of heterosexual transmission in the spread of HIV among men who have sex with men in South Africa. 21st International AIDS Conference: 18–22 July 2016; Durban, South Africa. Mulongeni P, Johnson L. Epidemiological synergy: the role of heterosexual transmission in the spread of HIV among men who have sex with men in South Africa. 21st International AIDS Conference: 18–22 July 2016; Durban, South Africa.
59.
go back to reference Nagelkerke NJD, Jha P, de Vlas SJ, Korenromp EL, Moses S, Blanchard JF, Plummer FA. Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. B World Health Organ. 2002;80(2):89–96. Nagelkerke NJD, Jha P, de Vlas SJ, Korenromp EL, Moses S, Blanchard JF, Plummer FA. Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. B World Health Organ. 2002;80(2):89–96.
60.
go back to reference Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS. 2005;19(1):1–14.CrossRefPubMed Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS. 2005;19(1):1–14.CrossRefPubMed
61.
go back to reference Garnett GP, Bartley L, Grassly NC, Anderson RM. Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings. Nat Med. 2002;8(7):651–4.CrossRefPubMed Garnett GP, Bartley L, Grassly NC, Anderson RM. Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings. Nat Med. 2002;8(7):651–4.CrossRefPubMed
62.
go back to reference Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, Doherty M, Revill P, Bertagnolio S. Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub-Saharan Africa. J Infect Dis. 2017;215(9):1362–5.CrossRefPubMedPubMedCentral Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, Doherty M, Revill P, Bertagnolio S. Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub-Saharan Africa. J Infect Dis. 2017;215(9):1362–5.CrossRefPubMedPubMedCentral
63.
go back to reference Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perriens JH, Venter F, Lundgren J, Phillips A. Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. AIDS. 2014;28(Suppl 1):S15–23.CrossRefPubMed Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perriens JH, Venter F, Lundgren J, Phillips A. Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. AIDS. 2014;28(Suppl 1):S15–23.CrossRefPubMed
64.
go back to reference Nichols BE, Sigaloff KC, Kityo C, Mandaliya K, Hamers RL, Bertagnolio S, Jordan MR, Boucher CA, Rinke de Wit TF, van de Vijver DA. Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study. AIDS. 2014;28(1):73–83.CrossRefPubMed Nichols BE, Sigaloff KC, Kityo C, Mandaliya K, Hamers RL, Bertagnolio S, Jordan MR, Boucher CA, Rinke de Wit TF, van de Vijver DA. Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study. AIDS. 2014;28(1):73–83.CrossRefPubMed
65.
go back to reference Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. J Infect Dis. 2013;208(2):224–34.CrossRefPubMedPubMedCentral Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. J Infect Dis. 2013;208(2):224–34.CrossRefPubMedPubMedCentral
66.
go back to reference van de Vijver DAMC, Nichols BE, Abbas UL, Boucher CAB, Cambiano V, Eaton JW, Glaubius R, Lythgoe K, Mellors J, Phillips A, et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS. 2013;27(18):2943–51.CrossRefPubMed van de Vijver DAMC, Nichols BE, Abbas UL, Boucher CAB, Cambiano V, Eaton JW, Glaubius R, Lythgoe K, Mellors J, Phillips A, et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS. 2013;27(18):2943–51.CrossRefPubMed
67.
go back to reference National Department of Health, Republic of South Africa. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents, and adults. Pretoria: National Department of Health, Republic of South Africa; 2015. National Department of Health, Republic of South Africa. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents, and adults. Pretoria: National Department of Health, Republic of South Africa; 2015.
68.
go back to reference Phillips AN, Cambiano V, Miners A, Revill P, Pillay D, Lundgren JD, Bennett D, Raizes E, Nakagawa F, De Luca A, et al. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV. 2014;1(2):e85–93.CrossRefPubMedPubMedCentral Phillips AN, Cambiano V, Miners A, Revill P, Pillay D, Lundgren JD, Bennett D, Raizes E, Nakagawa F, De Luca A, et al. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV. 2014;1(2):e85–93.CrossRefPubMedPubMedCentral
Metadata
Title
Combined interventions to reduce HIV incidence in KwaZulu-Natal: a modelling study
Authors
Stéphanie Blaizot
Helena Huerga
Benjamin Riche
Tom Ellman
Amir Shroufi
Jean-François Etard
René Ecochard
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2612-5

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.